HK Inno.N

HK Inno.N Enterprise Value

The Enterprise Value (EV) of HK Inno.N (195940.KQ) as of Nov 5, 2026 is 1.67 T KRW. In the previous year, Enterprise Value (EV) was 1.92 T KRW — a change of -13.00% (lower).

Enterprise Value

1.67 TKRW

YoY

-13.00%

Last updated:

Enterprise Value (EV) of HK Inno.N is 2025 1.67 T KRW. Enterprise Value (EV) of HK Inno.N was 2024 1.92 T KRW. It decreases by -13.00% lower compared to the previous year.

The HK Inno.N Enterprise Value history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Enterprise Value
Date
Enterprise Value
Jan 1, 2018
2.09 T KRW
Jan 1, 2019
2.10 T KRW
Jan 1, 2020
2.17 T KRW
Jan 1, 2021
1.82 T KRW
Jan 1, 2022
1.84 T KRW
Jan 1, 2023
1.84 T KRW
Jan 1, 2024
1.92 T KRW
Jan 1, 2025
1.67 T KRW
The HK Inno.N Enterprise Value history
YEAREnterprise ValueYoY
1.67 TKRW-13.00%
1.92 TKRW+4.48%
1.84 TKRW-0.13%
1.84 TKRW+1.24%
1.82 TKRW-16.35%
2.17 TKRW+3.62%
2.10 TKRW+0.39%
2.09 TKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

HK Inno.N Stock analysis

What does HK Inno.N do? HK inno.N Corp. generates revenue through its Prescription Drug segment, which manufactures and sells hormone drugs, anticancer drugs, high blood pressure drugs, gastroesophageal reflux disease drugs, blood nutrient supplies, and circulatory system products. The Health Beauty and Beverage (HB&B) segment contributes by producing and distributing hangover relieving products, health drinks, and food items. The Other segment earns income from trademark royalties and additional services. Products are sold domestically and internationally, targeting healthcare consumers and businesses seeking pharmaceutical and wellness solutions. The company's Prescription Drug segment focuses on specialized medical treatments, while HB&B targets health-conscious consumers with lifestyle products. Trademark royalties in the Other segment provide supplementary revenue from intellectual property licensing. Domestic sales form a significant portion of the business, with international markets expanding the company's reach. HK inno.N Corp. serves healthcare providers and end consumers through its Prescription Drug segment, with products like anticancer and high blood pressure drugs. HB&B products such as hangover relievers and health drinks cater to individual wellness needs. The Other segment’s trademark royalties support brand value, with sales spanning both local and global markets. HK Inno.N is one of the most popular companies on Eulerpool.

Frequently Asked Questions about HK Inno.N stock

Enterprise Value (EV) of HK Inno.N is 1.67 T KRW in 2025.

Enterprise Value (EV) of HK Inno.N changed from 1.92 T KRW to 1.67 T KRW, representing a -13.00% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Enterprise Value (EV) HK Inno.N since 2006 – with annual values, charts, and detailed analysis.

Enterprise Value represents the total value of a company, including both equity and debt, minus cash. It provides a more comprehensive picture than market capitalization alone.

EV = Market Capitalization + Total Debt - Cash & Equivalents

To evaluate Enterprise Value (EV)'s KRW, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Enterprise Value (EV).

A 'good' KRW varies by industry and company stage. On Eulerpool, you can compare Enterprise Value (EV)'s HK Inno.N with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — HK Inno.N

All Key Metrics — HK Inno.N